Metsera shares soar on positive amylin candidate trial results

Investing.com -- Shares of Metsera, Inc. (Nasdaq:MTSR) surged 18% following the announcement of positive Phase 1 trial results for its once-monthly amylin analog candidate, MET-233i. The New York-based biopharmaceutical company reported that MET-233i demonstrated up to 8.4% mean placebo-subtracted weight loss at Day 36, with a half-life supporting monthly dosing and a well-tolerated safety profile.

The randomized, placebo-controlled, double-blind trial assessed the pharmacokinetics, efficacy, and safety of MET-233i in participants with overweight or obesity without type 2 diabetes. Results indicated dose-linear pharmacokinetics and a 19-day observed half-life from dose to 50% of maximum concentration (Cmax), suggesting a potential for simplified once-monthly dosing. MET-233i also exhibited combinability with Metsera’s GLP-1 receptor agonist candidate, MET-097i, as a potential first-in-category monthly multi-NuSH combination.

Steve Marso, M.D., Chief Medical (TASE:BLWV) Officer of Metsera, expressed enthusiasm about the trial outcomes, highlighting the drug’s efficacy and safety. "We observed five-week body weight loss comparable to that of leading GLP-1-based medicines, and we identified efficacious starting doses with placebo-like tolerability. These data position MET-233i as a potential best-in-class amylin and support a category-leading profile in combination with MET-097i," said Marso.

The trial’s topline results also indicated favorable tolerability, with gastrointestinal adverse events being mild and dose-dependent. Importantly, no severe or serious adverse events were observed. The company plans to continue advancing MET-233i as a monotherapy and in combination with MET-097i, with additional trial data expected in late 2025 and beyond.

Metsera’s proprietary HALO™ platform technology underpins the development of MET-233i, which aims to offer patients a more convenient dosing schedule with substantial weight loss. The positive trial results have clearly resonated with investors, as evidenced by the significant uptick in Metsera’s stock price during the trading session.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.